Investment Rating - The report does not explicitly state an investment rating for the chemical industry Core Insights - In April 2025, the basic chemical index decreased by 3.61%, ranking 20th among primary industries, with 12 sub-industries showing growth and 20 experiencing declines [11][16][20] - The apparent consumption of methanol in China has surpassed 100 million tons for the first time [1] Market Overview - Major indices in April 2025 showed the following changes: Shanghai Composite Index -1.70%, Shenzhen Component Index -5.75%, ChiNext Index -7.40%, and North Securities 50 Index +4.72% [11] - The basic chemical sector's performance was mixed, with significant declines in rubber and related products, while daily chemical products and inorganic salts showed positive growth [16][20] Product Price Movements - The top ten products with price increases in April 2025 included Trichloroethylene (+16.28%), Ammonium Sulfate (+12.20%), and H Acid (+10.96%) [24][25] - Trichloroethylene prices rose significantly due to reduced production and strong demand in the refrigerant market [25][26] Sub-Industry Performance - Among the basic chemical sub-industries, the top five performers were daily chemicals (+8.56%), inorganic salts (+4.37%), and fluorochemicals (+3.46%), while polyurethane and tires saw the largest declines of -17.59% and -14.68%, respectively [16][19] - In April 2025, 221 companies in the basic chemical sector reported positive returns, while 319 reported negative returns [20] Company Performance - The top ten companies by monthly growth included United Chemical (+159.09%), Hongbaoli (+104.27%), and Zhongxin Fluorine Materials (+65.92%) [21][22] - Conversely, the bottom ten companies included Hunan YN (-22.18%), Dingjide (-22.54%), and Hengxing New Materials (-23.21%) [23][24] Industry News - In the first quarter of 2025, the chemical raw materials and products manufacturing industry achieved a total profit of 78.76 billion yuan, a slight decrease of 0.4% year-on-year [32] - Shandong province continues to enhance its chemical industry advantages, with 3,682 large-scale chemical enterprises and a revenue of 2.86 trillion yuan by the end of 2024 [32]

Group 1: Financial Performance - The company expects a revenue of 2.5 billion CNY for 2025, based on cautious analysis of market conditions and financial results from 2024 [2][3] - In Q1 2025, the company experienced a nearly 20% year-on-year increase in revenue, but net profit significantly declined due to increased R&D expenses and fixed asset depreciation [4] Group 2: Product Development and Market Strategy - The company has a 60,000-ton electronic-grade hydrogen peroxide project that can achieve G3 electronic-grade purity, applicable in electronics and photovoltaic sectors [2] - To ensure sales targets are met, the company is optimizing procurement strategies, enhancing production efficiency, and expanding overseas market presence [3] Group 3: Market Conditions and Stock Performance - The company's stock price is influenced by market conditions, industry developments, and investor preferences, despite normal operational performance [3] - The rise in sulfuric acid prices in Q1 positively impacted the company's revenue from sulfuric acid products [2]

Group 1 - The company, Anhui Huatai Chemical Co., Ltd., will hold an earnings briefing on April 30, 2025, from 15:30 to 16:30 [3][4] - The briefing will be conducted online via the platform "Value Online" [4] - Investors can submit questions before the briefing through a designated website or WeChat mini-program [5] Group 2 - Key participants in the briefing will include Chairman Wu Wei, Independent Director George Wu, CFO Fu Jinpeng, and Secretary of the Board Wang Yin [4] - The company aims to communicate its operational performance and development strategy during the briefing [3] - Contact information for inquiries includes a phone number and email address for further assistance [5][6]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 安徽华尔泰化工股份有限公司（以下简称"公司"）已于 2025 年 4 月 18 日在巨潮资讯网上披露了《2024 年年度报告全文》、《2024 年年度报告摘要》 及《2025 年第一季度报告》。为便于广大投资者更加全面深入地了解公司经营 业绩、发展战略等情况，公司定于 2025 年 4 月 30 日（星期三）15:30-16:30 在 "价值在线"（www.ir-online.cn）举办安徽华尔泰化工股份有限公司 2024 年度 会议召开时间：2025 年 4 月 30 日（星期三）15:30-16:30 会议召开方式：网络互动方式 会议召开地点：价值在线（www.ir-online.cn） 会议问题征集： 投资者可于 2025 年 4 月 30 日 前 访问网址 https://eseb.cn/1nEKlj81G00 或使用微信扫描下方小程序码进行会前提问， 公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注 的问题进行回答。 及 2025 年一季度业绩说明会，与投资者进行沟通和交流 ...

Core Viewpoint - Huatai (001217.SZ) reported a significant decline in both revenue and net profit for the year 2024, reflecting ongoing operational pressures in a challenging market environment [1][4]. Financial Performance - The total revenue for 2024 was 1.641 billion yuan, a decrease of 8.42% from 1.792 billion yuan in 2023 [4]. - The net profit attributable to shareholders fell to 87.74 million yuan, down 44.56% from 158 million yuan [4]. - The non-recurring net profit also dropped to 78.78 million yuan, a decline of 46.16% from 146 million yuan [4]. - This marks the third consecutive year of declining net profits, with net profits from 2022 to 2024 being 220 million yuan, 158 million yuan, and 87.74 million yuan, reflecting year-on-year declines of 47.12%, 27.98%, and 44.56% respectively [4]. Business Segment Performance - The basic chemical business generated revenue of 1.244 billion yuan, down 9.22%, with a gross margin of 17.84%, a decrease of 2.79 percentage points [5]. - The fine chemical business reported revenue of 397 million yuan, a decline of 5.81%, with a gross margin of only 0.27%, down 0.58 percentage points [5]. - Despite high capacity utilization rates for products like concentrated nitric acid (118%), hydrogen peroxide (96%), and sulfuric acid (88%), this did not translate into profit growth due to falling sales prices [5][6]. Research and Development - In 2024, the company invested 49.60 million yuan in R&D, a decrease of 10.64% year-on-year, indicating reduced investment in technological innovation [4][7]. - The company has made progress in project construction and technological innovation, including the successful commissioning of the ammonia synthesis project and readiness for the electronic-grade hydrogen peroxide project [7]. - Ongoing R&D projects include improvements in sulfur trioxide distillation, hydrogen peroxide product decarbonization, and extraction separation technologies, which are expected to enhance production capabilities [7]. Future Outlook - The company faces significant operational challenges with declining revenue and profit margins amid intensified market competition and rising costs [7]. - The ability to enhance profitability in a competitive landscape remains a critical issue for the company's future [7].

Core Viewpoint - The company, Hualitai, reported a decline in revenue and net profit for the year 2024, indicating ongoing challenges in the chemical industry due to macroeconomic factors and increased competition [1][2]. Financial Performance - In 2024, Hualitai achieved revenue of 1.641 billion yuan, a year-on-year decrease of 8.42% - Net profit for the same period was 87.74 million yuan, down 44.56% year-on-year - The company's net profit has been on a downward trend for three consecutive years, with figures of 220 million yuan, 158 million yuan, and 87.74 million yuan from 2022 to 2024, representing declines of 47.12%, 27.98%, and 44.56% respectively [1][2]. Quarterly Performance - For Q1 2025, Hualitai reported revenue of 471 million yuan, a year-on-year increase of 19.25% - However, net profit for the quarter was 17.03 million yuan, reflecting a significant decline of 48.9% year-on-year [1]. Industry Context - The decline in performance is attributed to several factors, including a slowdown in macroeconomic growth affecting downstream demand for chemical products, intensified market competition due to new capacity expansions, and increased operational costs from R&D and other expenses [1][2]. Product Segmentation - Hualitai's main products include nitric acid, sulfuric acid, hydrogen peroxide, and melamine, with a focus on both basic and fine chemicals - Revenue from the basic chemical segment was 1.244 billion yuan, down 9.22%, with a gross margin of 17.84%, a decrease of 2.79 percentage points - Revenue from the fine chemical segment was 397 million yuan, down 5.81%, with a gross margin of 0.27%, a decrease of 0.58 percentage points [2]. Capacity Utilization - The company maintains high capacity utilization rates for its main products, with nitric acid at 118%, hydrogen peroxide at 96%, and sulfuric acid at 88% [2]. Expansion and Upgrades - Hualitai is actively pursuing capacity expansion and technological upgrades, with projects such as the ammonia synthesis energy-saving upgrade and a new 150,000-ton nitric acid project completed on schedule - The company is also working on a 60,000-ton electronic-grade hydrogen peroxide project, which is ready for production [3]. Investment Project Performance - Many of Hualitai's initial public offering (IPO) fundraising projects have not met expected benefits - The 10,000-ton N-methyl morpholine project has incurred cumulative losses of 38.94 million yuan since its launch in 2022 - The 150,000-ton hydrogen peroxide project has achieved cumulative benefits of 46.75 million yuan, but did not meet the forecasted benefits due to changes in market conditions - The cogeneration project has also fallen short of expectations, with cumulative benefits of 34.87 million yuan due to insufficient steam demand from downstream users [3]. Dividend Distribution - Hualitai plans to distribute a cash dividend of 1 yuan per 10 shares to all shareholders in 2024, amounting to approximately 33.19 million yuan, which represents 37.82% of its net profit [4].

2024 年度募集资金存放与使用情况的核查意见 恒泰长财证券有限责任公司（以下简称"保荐机构"或"恒泰长财证券"）作 为安徽华尔泰化工股份有限公司（以下简称"华尔泰"或"公司"）首次公开发行 股票的保荐机构，根据《证券发行上市保荐业务管理办法》、 《深圳证券交易所 上市公司自律监管指引第 13 号—保荐业务》、《深圳证券交易所上市公司自律监管 指引第 1 号—主板上市公司规范运作》、《上市公司监管指引第 2 号—上市公司募 集资金管理和使用的监管要求》等有关法律法规和规范性文件的要求，对公司 2024 年度募集资金存放与使用情况进行了审慎核查，核查情况及核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于核准安徽华尔泰化工股份有限公司首次公 开发行股票的批复》证监许可[2021]2915 号核准，公司于 2021 年 9 月采取网下向 符合条件的投资者询价配售和网上向持有深圳市场非限售 A 股股份及非限售存托 凭证市值的社会公众投资者定价发行相结合的方式，公开发行人民币普通股（A 股） 8,297.00 万股，每股发行价格为人民币 10.46 元，应募集资 ...

目 录 | 序号 | 内 容 | 页码 | | --- | --- | --- | | 1 | 募集资金年度存放与使用情况鉴证报告 | 1-2 | | 2 | 募集资金年度存放与使用情况专项报告 | 3-9 | 募集资金年度存放与使用情况鉴证报告 安徽华尔泰化工股份有限公司 容诚专字[2025]230Z0972 号 容诚会计师事务所(特殊普通合伙) 中国·北京 募集资金年度存放与使用情况鉴证报告 容诚专字[2025]230Z0972 号 安徽华尔泰化工股份有限公司全体股东： 我们审核了后附的安徽华尔泰化工股份有限公司（以下简称华尔泰公司）董 事会编制的 2024 年度《关于募集资金年度存放与使用情况的专项报告》。 一、 对报告使用者和使用目的的限定 本鉴证报告仅供华尔泰公司年度报告披露之目的使用，不得用作任何其他目 的。我们同意将本鉴证报告作为华尔泰公司年度报告必备的文件，随其他文件一 起报送并对外披露。 二、 董事会的责任 按照中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》、深圳证券交易所《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作 ...

内部控制审计报告 安徽华尔泰化工股份有限公司 容诚审字[2025]230Z1428 号 容诚会计师事务所(特殊普通合伙) 中国·北京 内部控制审计报告 容诚审字[2025]230Z1428 号 安徽华尔泰化工股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求，我 们审计了安徽华尔泰化工股份有限公司（以下简称"华尔泰公司"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外，由于 情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 四、财务报告内部控制审计意见 我们认为，华尔泰公司于 2024 年 12 月 31 日按照《企业内部控制基本规范》 和相关规定在所有重大方面保持了有效的财务报告内部控制。 1 （此页无正文，为安徽华尔泰化工股份有限公司容诚审字[2025]230Z1428 号 报告之签字盖章页。） 容诚会计师事务所 （特殊普通合伙） 中国注册会计师： 周文亮 按照 ...

安徽华尔泰化工股份有限公司 容诚专字[2025]230Z0973 号 容诚会计师事务所(特殊普通合伙) 中国·北京 关于安徽华尔泰化工股份有限公司 非经营性资金占用及其他关联资金往来情况专项说明 非经营性资金占用及其他关联资金 往来情况专项说明 中国注册会计师： 容诚专字[2025]230Z0973 号 安徽华尔泰化工股份有限公司全体股东： 我们接受委托，依据中国注册会计师审计准则审计了安徽华尔泰化工股份有 限公司（以下简称华尔泰公司）2024 年 12 月 31 日的合并及母公司资产负债表， 2024 年度的合并及母公司利润表、合并及母公司现金流量表和合并及母公司所有 者权益变动表以及财务报表附注，并于 2025 年 4 月 16 日出具了容诚审字 [2025]230Z1427 号的标准无保留意见审计报告。 根据中国证券监督管理委员会《上市公司监管指引第 8 号——上市公司资金 往来、对外担保的监管要求》的要求及深圳证券交易所《深圳证券交易所上市公司 自律监管指南第 1 号——业务办理》的规定，华尔泰公司管理层编制了后附的安 徽华尔泰化工股份有限公司 2024 年度非经营性资金占用及其他关联资金往来情况 汇 ...